L. Hamm

The effect of the 5‐HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients

M. Mandelkern, L. Chang, S. Berman, 2002, Alimentary pharmacology & therapeutics.

Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron.

Leah Fitzgerald, Lin Chang, Jean Stains, 2002, Gastroenterology.

Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria

C. Hunt, A. Mangel, G. Kapke, 1999, American Journal of Gastroenterology.